Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Weekly News Recap #Phispers
1. Ch5126766
2. Ro5126766
1. 946128-88-7
2. Ro5126766
3. Ro-5126766
4. Ch5126766
5. Ro-5126766 Free Base
6. Avutometinib
7. Ro 5126766
8. Ch-5126766
9. Rg-7304
10. Cki-27
11. Ro5126766(ch5126766)
12. Chebi:78825
13. Ro 5126766 - Bio-x
14. Vs-6766
15. Chembl3264002
16. Ro5126766 (ch5126766)
17. D0d4252v97
18. R-7304
19. N-(3-fluoro-4-{[4-methyl-2-oxo-7-(pyrimidin-2-yloxy)-2h-chromen-3-yl]methyl}pyridin-2-yl)-n'-methylsulfuric Diamide
20. Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2h-1-benzopyran-3-yl)methyl)-2-pyridinyl)-n'-methyl-
21. 3wig
22. Chu
23. Avutometinib [inn]
24. Schembl960093
25. Unii-d0d4252v97
26. Gtpl11867
27. Bcp21067
28. Ex-a2151
29. Bdbm50010462
30. Nsc758248
31. Nsc800871
32. S7170
33. Zinc68247388
34. Akos030527032
35. Ccg-269457
36. Compound 1 [pmid: 24900832]
37. Cs-5254
38. Db15254
39. Nsc-758248
40. Nsc-800871
41. Sb16628
42. Ro 5126766 [who-dd]
43. Ac-35949
44. Da-40233
45. Hy-18652
46. Ch 5126766
47. Ft-0737411
48. A916428
49. Ro5126766; Ch5126766
50. Q27147976
51. Ro 5126766; Ro5126766; Ch5126766; Ch5126766; Ch 5126766
52. 3-[(2-((n-methylsulfamoyl)amino)-3-fluoropyridin-4-yl)methyl]-4-methyl-7-(pyrimidin-2-yloxy)-chromen-2-one
53. 3-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-4-methyl-7-pyrimidin-2-yloxychromen-2-one
54. N-(3-fluoro-4-((4-methyl-2-oxo-7-(pyrimidin-2-yloxy)-2h-chromen-3-yl)methyl)pyridin-2-yl)-n'-methylsulfamide
| Molecular Weight | 471.5 g/mol |
|---|---|
| Molecular Formula | C21H18FN5O5S |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 7 |
| Exact Mass | 471.10126803 g/mol |
| Monoisotopic Mass | 471.10126803 g/mol |
| Topological Polar Surface Area | 141 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 845 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Avutometinib is a Miscellaneous drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Endometrial Neoplasms.
Lead Product(s): Verastem Oncology,Avutometinib,Defactinib,16719221,Everolimus,Approved API
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Verastem Oncology
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2026
Lead Product(s) : Verastem Oncology,Avutometinib,Defactinib,16719221,Everolimus,Approved API
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Verastem Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Avutometinib is a Miscellaneous drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Endometrial Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 06, 2026
Details:
The proceeds from the offering will be used to fund the clinical development of Avutometinib for KRAS-mutated recurrent Low-Grade Serous Ovarian Cancer.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: Avmapkitm Fakzynjatm Co-Pack
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Jefferies | Guggenheim Securities | Cantor
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 14, 2025
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Jefferies | Guggenheim Securities | Cantor
Deal Size : $90.0 million
Deal Type : Public Offering
Verastem Oncology Prices $90M Public Offering of Common Stock and Warrants
Details : The proceeds from the offering will be used to fund the clinical development of Avutometinib for KRAS-mutated recurrent Low-Grade Serous Ovarian Cancer.
Product Name : Avmapkitm Fakzynjatm Co-Pack
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 14, 2025
Details:
The proceeds from the offering will be used to fund the clinical development of Avutometinib for KRAS-mutated recurrent Low-Grade Serous Ovarian Cancer.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: Avmapkitm Fakzynjatm Co-Pack
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Jefferies | Guggenheim Securities | Cantor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering November 13, 2025
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Jefferies | Guggenheim Securities | Cantor
Deal Size : Undisclosed
Deal Type : Public Offering
Verastem Oncology Plans Public Offering of Common Stock
Details : The proceeds from the offering will be used to fund the clinical development of Avutometinib for KRAS-mutated recurrent Low-Grade Serous Ovarian Cancer.
Product Name : Avmapkitm Fakzynjatm Co-Pack
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 13, 2025
Details:
Defactinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Pancreatic Neoplasms.
Lead Product(s): Defactinib,Avutometinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Verastem Oncology | Foundation for Barnes-Jewish Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 17, 2025
Lead Product(s) : Defactinib,Avutometinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Verastem Oncology | Foundation for Barnes-Jewish Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Radiotherapy Plus FAK & RAF/MEK Inhibitors in Advanced Pancreatic Adenocarcinoma
Details : Defactinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 17, 2025
Details:
Through the collaboration, Tempus completed testing in Verastem’s trial, which evaluated the combination of VS-6766 (avutometinib) and defactinib to treat recurrent low-grade serous ovarian cancer.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Verastem Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 20, 2025
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Verastem Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
Tempus, Verastem Collaborate on CDx for KRAS-Mutant Ovarian Cancer Combo Therapy
Details : Through the collaboration, Tempus completed testing in Verastem’s trial, which evaluated the combination of VS-6766 (avutometinib) and defactinib to treat recurrent low-grade serous ovarian cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 20, 2025
Details:
Avmapki Fakzynja Co-Pack, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with KRAS-mutated recurrent LGSOC.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: Avmapki Fakzynja Co-Pack
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 08, 2025
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Avmapki & Fakzynja Combo for KRAS-Mutated Ovarian Cancer
Details : Avmapki Fakzynja Co-Pack, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with KRAS-mutated recurrent LGSOC.
Product Name : Avmapki Fakzynja Co-Pack
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 08, 2025
Details:
The proceeds from the financing are expected to fund the potential launch of VS-6766 (avutometinib) and defactinib in recurrent low-grade serous ovarian cancer.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: RTW Investments
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 25, 2025
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : RTW Investments
Deal Size : $75.0 million
Deal Type : Private Placement
Verastem Oncology Announces $75 million Private Placement
Details : The proceeds from the financing are expected to fund the potential launch of VS-6766 (avutometinib) and defactinib in recurrent low-grade serous ovarian cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 25, 2025
Details:
The financing aims to advance the clinical development of company's lead product, VS-6766 (Avutometinib) plus defactinib. It is being evaluated for the KRAS mutant low-grade serous ovarian cancer.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Oberland Capital Management
Deal Size: $157.5 million Upfront Cash: Undisclosed
Deal Type: Financing January 13, 2025
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Oberland Capital Management
Deal Size : $157.5 million
Deal Type : Financing
Verastem Oncology Announces Debt Refinancing, Partnership for Ovarian Cancer
Details : The financing aims to advance the clinical development of company's lead product, VS-6766 (Avutometinib) plus defactinib. It is being evaluated for the KRAS mutant low-grade serous ovarian cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 13, 2025
Details:
Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adults with recurrent KRAS mutant low-grade serous ovarian cancer.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 30, 2024
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Verastem Oncology Announces FDA Acceptance Of Avutometinib + Defactinib NDA
Details : Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adults with recurrent KRAS mutant low-grade serous ovarian cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 30, 2024
Details:
Combination of avutometinib, a RAF/MEK clamp with sotorasib & defactinib, , being developed for the treatment of KRAS G12C mutant non-small cell lung cancer.
Lead Product(s): Avutometinib,Defactinib,Sotorasib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 18, 2024
Lead Product(s) : Avutometinib,Defactinib,Sotorasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Verastem Oncology Provides Clinical Update on RAMP 203 Trial in KRAS G12C Mutant NSCLC
Details : Combination of avutometinib, a RAF/MEK clamp with sotorasib & defactinib, , being developed for the treatment of KRAS G12C mutant non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 18, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : RX
Registration Country : USA
AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE
Brand Name : AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
Dosage Form : CAPSULE, TABLET;ORAL
Dosage Strength : EQ 0.8MG BASE;EQ 200MG BASE
Packaging :
Approval Date : 2025-05-08
Application Number : 219616
Regulatory Info : RX
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD : Yes
TE Code :
AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE
Brand Name : AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
Dosage Form : CAPSULE, TABLET;ORAL
Dosage Strength : EQ 0.8MG BASE;EQ 200MG BASE
Approval Date : 2025-05-08
Application Number : 219616
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
98
PharmaCompass offers a list of Avutometinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Avutometinib manufacturer or Avutometinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Avutometinib manufacturer or Avutometinib supplier.
PharmaCompass also assists you with knowing the Avutometinib API Price utilized in the formulation of products. Avutometinib API Price is not always fixed or binding as the Avutometinib Price is obtained through a variety of data sources. The Avutometinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Avutometinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Avutometinib, including repackagers and relabelers. The FDA regulates Avutometinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Avutometinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Avutometinib supplier is an individual or a company that provides Avutometinib active pharmaceutical ingredient (API) or Avutometinib finished formulations upon request. The Avutometinib suppliers may include Avutometinib API manufacturers, exporters, distributors and traders.
Avutometinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Avutometinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Avutometinib GMP manufacturer or Avutometinib GMP API supplier for your needs.
A Avutometinib CoA (Certificate of Analysis) is a formal document that attests to Avutometinib's compliance with Avutometinib specifications and serves as a tool for batch-level quality control.
Avutometinib CoA mostly includes findings from lab analyses of a specific batch. For each Avutometinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Avutometinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Avutometinib EP), Avutometinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Avutometinib USP).
